Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 3 (March)

1. Triple-negative breast cancer: therapeutic options.
   Lancet Oncol, 8(3): 235-44. [Abstract] [Full-text]
2. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
   Lancet Oncol, 8(3): 219-25. [Abstract] [Full-text]
3. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.
   Lancet Oncol, 8(3): 203-11. [Abstract] [Full-text]
4. A gene-expression signature to predict survival in breast cancer across independent data sets.
   Oncogene, 26(10): 1507-16. [Abstract] [Full-text]
5. Cigarette smoke condensate-induced level of adenomatous polyposis coli blocks long-patch base excision repair in breast epithelial cells.
   Oncogene, 26(10): 1428-38. [Abstract] [Full-text]
6. Radiological and pathological findings of interval cancers in a multi-centre, randomized, controlled trial of mammographic screening in women from age 40-41 years.
   Clin Radiol, 62(4): 348-52. [Abstract] [Full-text]
7. Risk perception, worry and satisfaction related to genetic counseling for hereditary cancer.
   J Genet Couns, 16(2): 211-22. [Abstract] [Full-text]
8. Increasing utilization of cancer genetic counseling services using a patient navigator model.
   J Genet Couns, 16(2): 171-7. [Abstract] [Full-text]
9. Non-inflammatory skin involvement in breast cancer, histologically proven but without the clinical and histological T4 category features.
   J Surg Oncol, 95(4): 291-7. [Abstract] [Full-text]
10. Estrogens decrease gamma-ray-induced senescence and maintain cell cycle progression in breast cancer cells independently of p53.
    Int J Radiat Oncol Biol Phys, 67(4): 1187-200. [Abstract] [Full-text]
11. Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy.
    Int J Radiat Oncol Biol Phys, 67(4): 1163-71. [Abstract] [Full-text]
12. Adjuvant stereotactic permanent seed breast implant: a boost series in view of partial breast irradiation.
    Int J Radiat Oncol Biol Phys, 67(4): 1052-8. [Abstract] [Full-text]
13. Long-term outcomes in breast cancer patients with ten or more positive axillary nodes treated with combined-modality therapy: the importance of radiation field selection.
    Int J Radiat Oncol Biol Phys, 67(4): 1043-51. [Abstract] [Full-text]
14. Direct aperture optimization-based intensity-modulated radiotherapy for whole breast irradiation.
    Int J Radiat Oncol Biol Phys, 67(4): 1248-58. [Abstract] [Full-text]
15. Psychological attitudes and risk of breast cancer in Japan: a prospective study.
    Cancer Causes Control, 18(3): 259-67. [Abstract] [Full-text]
16. The black:white disparity in breast cancer mortality: the example of Chicago.
    Cancer Causes Control, 18(3): 323-33. [Abstract] [Full-text]
17. Examining predictive models of HRQOL in a population-based, multiethnic sample of women with breast carcinoma.
    Qual Life Res, 16(3): 413-28. [Abstract] [Full-text]
18. Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer.
    Cancer Lett, 248(1): 131-6. [Abstract] [Full-text]
19. Aurora-A amplification associated with BRCA2 mutation in breast tumours.
    Cancer Lett, 248(1): 96-102. [Abstract] [Full-text]
20. Links between DNA double strand break repair and breast cancer: accumulating evidence from both familial and nonfamilial cases.
    Cancer Lett, 248(1): 1-17. [Abstract] [Full-text]
21. Doctor-patient relationship as motivation and outcome: examining uses of an Interactive Cancer Communication System.
    Int J Med Inform, 76(4): 274-82. [Abstract] [Full-text]
22. Optical mammography: a new technique for visualizing breast lesions in women presenting non palpable BIRADS 4-5 imaging findings: preliminary results with radiologic-pathologic correlation.
    Cancer Imaging, 7: 34-40. [Abstract] [Full-text]
23. Tamoxifen: important considerations of a multi-functional compound with organ-specific properties.
    Cancer Treat Rev, 33(2): 91-100. [Abstract] [Full-text]
24. Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells.
    Biochem Biophys Res Commun, 355(3): 700-6. [Abstract] [Full-text]
25. Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?
    Crit Rev Oncol Hematol, 62(1): 1-8. [Abstract] [Full-text]
26. The EGF receptor interacts with the type 1 IGF receptor and regulates its stability.
    Biochem Biophys Res Commun, 355(3): 707-14. [Abstract] [Full-text]
27. Individual differences in well-being in older breast cancer survivors.
    Crit Rev Oncol Hematol, 62(1): 74-83. [Abstract] [Full-text]
28. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors.
    J Control Release, 118(2): 216-24. [Abstract] [Full-text]
29. Impact of breast cancer survivorship on quality of life in older women.
    Crit Rev Oncol Hematol, 62(1): 84-91. [Abstract] [Full-text]
30. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
    Cancer Lett, 248(2): 308-20. [Abstract] [Full-text]
31. Rugosin E, an ellagitannin, inhibits MDA-MB-231 human breast cancer cell proliferation and induces apoptosis by inhibiting nuclear factor-kappaB signaling pathway.
    Cancer Lett, 248(2): 280-91. [Abstract] [Full-text]
32. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
    Cancer Lett, 248(2): 165-74. [Abstract] [Full-text]
33. Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives.
    Cancer Lett, 248(2): 175-85. [Abstract] [Full-text]
34. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk.
    J Natl Cancer Inst, 99(5): 386-95. [Abstract] [Full-text]
35. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.
    J Natl Cancer Inst, 99(5): 365-75. [Abstract] [Full-text]
36. SERMs: meeting the promise of multifunctional medicines.
    J Natl Cancer Inst, 99(5): 350-6. [Abstract] [Full-text]
37. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
    Int J Cancer, 120(9): 1874-82. [Abstract] [Full-text]
38. The 8-epimer of prostaglandin F(2alpha), a marker of lipid peroxidation and oxidative stress, is decreased in the nipple aspirate fluid of women with breast cancer.
    Int J Cancer, 120(9): 1971-6. [Abstract] [Full-text]
39. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines.
    Int J Cancer, 120(9): 1883-90. [Abstract] [Full-text]
40. Benefits of supervised group exercise programme for women being treated for early stage breast cancer: pragmatic randomised controlled trial.
    BMJ, 334(7592): 517. [Abstract] [Full-text]
41. Calcium regulates tertiary structure and enzymatic activity of human endometase/matrilysin-2 and its role in promoting human breast cancer cell invasion.
    Biochem J, 403(1): 31-42. [Abstract] [Full-text]
42. Adjustment of children and their mothers with breast cancer.
    J Pediatr Psychol, 32(3): 297-308. [Abstract] [Full-text]
43. Accelerated partial breast irradiation in early-stage breast cancer.
    J Clin Oncol, 25(8): 996-1002. [Abstract] [Full-text]
44. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study.
    Anticancer Drugs, 18(4): 477-85. [Abstract] [Full-text]
45. Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumors.
    J Biol Chem, 282(11): 8325-31. [Abstract] [Full-text]
46. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy.
    Patient Educ Couns, 66(1): 108-18. [Abstract] [Full-text]
47. Vitality, mental health, and satisfaction with information after breast cancer.
    Patient Educ Couns, 66(1): 58-66. [Abstract] [Full-text]
48. Canadian breast cancer guidelines: have they made a difference?
    CMAJ, 176(6): 771-6. [Abstract] [Full-text]
49. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies.
    Int J Cancer, 120(8): 1721-30. [Abstract] [Full-text]
50. Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer.
    Int J Cancer, 120(8): 1664-8. [Abstract] [Full-text]
51. Evaluation of zinc status in whole blood and scalp hair of female cancer patients.
    Clin Chim Acta, 379(1): 66-70. [Abstract] [Full-text]
52. Mapping of angiogenic markers for targeting of vectors to tumor vascular endothelial cells.
    Cancer Gene Ther, 14(4): 346-53. [Abstract] [Full-text]
53. A recurrent mutation in PALB2 in Finnish cancer families.
    Nature, 446(7133): 316-9. [Abstract] [Full-text]
54. Transfer of follow-up care to family physicians for early-stage breast cancer.
    Clin Oncol (R Coll Radiol), 19(3): 172-6. [Abstract] [Full-text]
55. Mucinous carcinoma of breast with abundant psammoma bodies in fine-needle aspiration cytology: a case report.
    Diagn Cytopathol, 35(4): 230-3. [Abstract] [Full-text]
56. A new molecular breast cancer subclass defined from a large scale real-time quantitative RT-PCR study.
    BMC Cancer, 7: 39. [Abstract] [Full-text]
57. Mullerian-inhibiting substance induces Gro-beta expression in breast cancer cells through a nuclear factor-kappaB-dependent and Smad1-dependent mechanism.
    Cancer Res, 67(6): 2747-56. [Abstract] [Full-text]
58. Integrin alpha v beta 3 controls activity and oncogenic potential of primed c-Src.
    Cancer Res, 67(6): 2693-700. [Abstract] [Full-text]
59. Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines.
    Cancer Res, 67(6): 2657-65. [Abstract] [Full-text]
60. Lens epithelium-derived growth factor is an Hsp70-2 regulated guardian of lysosomal stability in human cancer.
    Cancer Res, 67(6): 2559-67. [Abstract] [Full-text]
61. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells.
    Cancer Res, 67(6): 2396-401. [Abstract] [Full-text]
62. Cost as a barrier to screening mammography among underserved women.
    Ethn Health, 12(2): 189-203. [Abstract] [Full-text]
63. Alcohol intake and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC).
    Cancer Causes Control, 18(4): 361-73. [Abstract] [Full-text]
64. DNA content and chromatin texture of human breast epithelial cells transformed with 17-beta-estradiol and the estrogen antagonist ICI 182,780 as assessed by image analysis.
    Mutat Res, 617(1): 1-7. [Abstract] [Full-text]
65. Estimating age-specific breast cancer risks: a descriptive tool to identify age interactions.
    Cancer Causes Control, 18(4): 439-47. [Abstract] [Full-text]
66. Antiproliferative effect of Erycibe elliptilimba on human breast cancer cell lines.
    J Ethnopharmacol, 110(3): 439-43. [Abstract] [Full-text]
67. Racial disparities in treatment and survival of male breast cancer.
    J Clin Oncol, 25(9): 1089-98. [Abstract] [Full-text]
68. Surveillance testing among survivors of early-stage breast cancer.
    J Clin Oncol, 25(9): 1074-81. [Abstract] [Full-text]
69. Decision aids and breast cancer: do they influence choice for surgery and knowledge of treatment options?
    J Clin Oncol, 25(9): 1067-73. [Abstract] [Full-text]
70. Usefulness of breast-volume replacement using an inframammary adipofascial flap after breast-conservation therapy.
    Am J Surg, 193(4): 514-8. [Abstract] [Full-text]
71. Physical activity, body mass index, and mammographic density in postmenopausal breast cancer survivors.
    J Clin Oncol, 25(9): 1061-6. [Abstract] [Full-text]
72. Breast cancer and the "materiality of risk": the rise of morphological prediction.
    Bull Hist Med, 81(1): 241-66. [Abstract] [Full-text]
73. Ill patient, public activist: Rose Kushner's attack on breast cancer chemotherapy.
    Bull Hist Med, 81(1): 224-40. [Abstract] [Full-text]
74. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels.
    J Steroid Biochem Mol Biol, 104(1): 27-34. [Abstract] [Full-text]
75. 5-Alkynyl-2'-deoxyuridines: chromatography-free synthesis and cytotoxicity evaluation against human breast cancer cells.
    Bioorg Med Chem, 15(8): 3082-8. [Abstract] [Full-text]
76. Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2.
    Bioorg Med Chem, 15(8): 2892-7. [Abstract] [Full-text]
77. Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells.
    Vaccine, 25(14): 2610-9. [Abstract] [Full-text]
78. Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells.
    J Steroid Biochem Mol Biol, 104(1): 11-21. [Abstract] [Full-text]
79. A longitudinal study of depression, pain, and stress as predictors of sleep disturbance among women with metastatic breast cancer.
    Biol Psychol, 75(1): 37-44. [Abstract] [Full-text]
80. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
    Magn Reson Imaging, 25(3): 319-27. [Abstract] [Full-text]
81. Magnetic resonance imaging measurements of vascular permeability and extracellular volume fraction of breast tumors by dynamic Gd-DTPA-enhanced relaxometry.
    Magn Reson Imaging, 25(3): 293-302. [Abstract] [Full-text]
82. Regulation of Nod1-mediated signaling pathways.
    Cell Death Differ, 14(4): 830-9. [Abstract] [Full-text]
83. Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study.
    Cancer Chemother Pharmacol, 59(6): 703-9. [Abstract] [Full-text]
84. Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status.
    J Natl Cancer Inst, 99(6): 475-86. [Abstract] [Full-text]
85. Dietary fat and postmenopausal invasive breast cancer in the National Institutes of Health-AARP Diet and Health Study cohort.
    J Natl Cancer Inst, 99(6): 451-62. [Abstract] [Full-text]
86. When you look matters: the effect of assessment schedule on progression-free survival.
    J Natl Cancer Inst, 99(6): 428-32. [Abstract] [Full-text]
87. Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor.
    Expert Opin Biol Ther, 7(4): 487-91. [Abstract] [Full-text]
88. Cancer stem cells--an old idea that's new again: implications for the diagnosis and treatment of breast cancer.
    Expert Opin Biol Ther, 7(4): 431-8. [Abstract] [Full-text]
89. FOXA1 as a therapeutic target for breast cancer.
    Expert Opin Ther Targets, 11(4): 507-14. [Abstract] [Full-text]
90. New perspectives into the biological and clinical relevance of oestrogen receptors in the human breast.
    J Pathol, 211(5): 499-506. [Abstract] [Full-text]
91. Normal tissue complication probability modelling of tissue fibrosis following breast radiotherapy.
    Phys Med Biol, 52(7): 1831-43. [Abstract] [Full-text]
92. Management of cancer-associated thrombotic microangiopathy: what is the right approach?
    Am J Hematol, 82(4): 295-8. [Abstract] [Full-text]
93. Cancer-related fatigue: "It's so much more than just being tired".
    Eur J Oncol Nurs, 11(2): 117-25. [Abstract] [Full-text]
94. Mechanisms of disease: adipokines and breast cancer - endocrine and paracrine mechanisms that connect adiposity and breast cancer.
    Nat Clin Pract Endocrinol Metab, 3(4): 345-54. [Abstract] [Full-text]
95. Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers.
    Oncogene, 26(13): 1959-70. [Abstract] [Full-text]
96. Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals.
    Oncogene, 26(13): 1941-8. [Abstract] [Full-text]
97. Expression of aberrant mucins in lobular carcinoma with histiocytoid feature of the breast.
    Virchows Arch, 450(4): 397-403. [Abstract] [Full-text]
98. Expression of the breast differentiation antigen NY-BR-1 in a phyllodes tumor of the vulva.
    Virchows Arch, 450(4): 471-4. [Abstract] [Full-text]
99. Unusual breast enlargement in an infant: a case of breast lipoblastoma.
    Pediatr Surg Int, 23(4): 361-3. [Abstract] [Full-text]
100. Treatment and survival from breast cancer: the experience of patients at South Australian teaching hospitals between 1977 and 2003.
     J Eval Clin Pract, 13(2): 212-20. [Abstract] [Full-text]
101. Chemical modulation of VLA integrin affinity in human breast cancer cells.
     Exp Cell Res, 313(6): 1121-34. [Abstract] [Full-text]
102. Characterization of Bizzy Nut extracts in estrogen-responsive MCF-7 breast cancer cells.
     Toxicol Appl Pharmacol, 220(1): 25-32. [Abstract] [Full-text]
103. Shaping the future of biomarker research in breast cancer to ensure clinical relevance.
     Nat Rev Cancer, 7(4): 309-15. [Abstract] [Full-text]
104. Perpendicular inked versus tangential shaved margins in breast-conserving surgery: does the method matter?
     J Am Coll Surg, 204(4): 541-9. [Abstract] [Full-text]
105. Antiangiogenic properties of metronomic chemotherapy in breast cancer.
     Future Oncol, 3(2): 183-90. [Abstract] [Full-text]
106. Phyllodes tumors of the breast segregate in two groups according to genetic criteria.
     Mod Pathol, 20(4): 435-44. [Abstract] [Full-text]
107. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer.
     Mod Pathol, 20(4): 474-81. [Abstract] [Full-text]
108. Quantifying tumour-infiltrating lymphocyte subsets: a practical immuno-histochemical method.
     J Immunol Methods, 321(1): 32-40. [Abstract] [Full-text]
109. PTHrP P3 promoter activity in breast cancer cell lines: role of Ets1 and CBP (CREB binding protein).
     Mol Cell Endocrinol, 268(1): 75-84. [Abstract] [Full-text]
110. Factors affecting health-related quality of life in women with recurrent breast cancer in Korea.
     Qual Life Res, 16(4): 559-69. [Abstract] [Full-text]
111. Body size and risk for breast cancer in relation to estrogen and progesterone receptor status in Japan.
     Ann Epidemiol, 17(4): 304-12. [Abstract] [Full-text]
112. Low-energy-loss electron microscopy of doxorubicin in human breast cancer MCF-7 cells: localization by color.
     J Struct Biol, 158(1): 80-92. [Abstract] [Full-text]
113. Pectoral stretching program for women undergoing radiotherapy for breast cancer.
     Breast Cancer Res Treat, 102(3): 313-21. [Abstract] [Full-text]
114. Sentinel node identification rate, but not accuracy, is significantly decreased after pre-operative chemotherapy in axillary node-positive breast cancer patients.
     Breast Cancer Res Treat, 102(3): 283-8. [Abstract] [Full-text]
115. Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer.
     Breast Cancer Res Treat, 102(3): 357-63. [Abstract] [Full-text]
116. Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden.
     Breast Cancer Res Treat, 102(3): 289-99. [Abstract] [Full-text]
117. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
     Breast Cancer Res Treat, 102(3): 301-12. [Abstract] [Full-text]
118. Reproductive factors and breast cancer risk among older women.
     Breast Cancer Res Treat, 102(3): 365-74. [Abstract] [Full-text]
119. MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells.
     Breast Cancer Res Treat, 102(3): 253-61. [Abstract] [Full-text]
120. Changes in risk of death from breast cancer with season and latitude: sun exposure and breast cancer survival in Norway.
     Breast Cancer Res Treat, 102(3): 323-8. [Abstract] [Full-text]
121. Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility: a case-control analysis.
     Breast Cancer Res Treat, 102(3): 329-37. [Abstract] [Full-text]
122. Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?
     Breast Cancer Res Treat, 102(3): 347-56. [Abstract] [Full-text]
123. Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer.
     Breast Cancer Res Treat, 102(3): 375-81. [Abstract] [Full-text]
124. AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib.
     Breast Cancer Res Treat, 102(3): 275-82. [Abstract] [Full-text]
125. The association between the pre-diagnosis mammography screening interval and advanced breast cancer.
     Breast Cancer Res Treat, 102(3): 339-45. [Abstract] [Full-text]
126. Mitochondrial DNA G10398A polymorphism imparts maternal Haplogroup N a risk for breast and esophageal cancer.
     Cancer Lett, 249(2): 249-55. [Abstract] [Full-text]
127. The use of molecular assays to establish definitively the clonality of ipsilateral breast tumor recurrences and patterns of in-breast failure in patients with early-stage breast cancer treated with breast-conserving therapy.
     Cancer, 109(7): 1264-72. [Abstract] [Full-text]
128. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.
     Cancer, 109(7): 1255-63. [Abstract] [Full-text]
129. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials.
     Cancer, 109(7): 1239-46. [Abstract] [Full-text]
130. Patient variables that predict atypical cytology by nipple duct lavage.
     Cancer, 109(7): 1247-54. [Abstract] [Full-text]
131. Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy.
     Ann Oncol, 18(4): 694-700. [Abstract] [Full-text]
132. The organisation and results of first screening round of the Hungarian nationwide organised breast cancer screening programme.
     Ann Oncol, 18(4): 795-9. [Abstract] [Full-text]
133. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials.
     Ann Oncol, 18(4): 701-8. [Abstract] [Full-text]
134. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study.
     Ann Oncol, 18(4): 689-93. [Abstract] [Full-text]
135. A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity.
     Ann Oncol, 18(4): 768-74. [Abstract] [Full-text]
136. A systematic review of common conservative therapies for arm lymphoedema secondary to breast cancer treatment.
     Ann Oncol, 18(4): 639-46. [Abstract] [Full-text]
137. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer.
     N Engl J Med, 356(13): 1295-303. [Abstract] [Full-text]
138. MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats.
     Radiology, 243(1): 105-11. [Abstract] [Full-text]
139. Solid breast masses: neural network analysis of vascular features at three-dimensional power Doppler US for benign or malignant classification.
     Radiology, 243(1): 56-62. [Abstract] [Full-text]
140. A modified approach for I-FISH evaluation of ERBB2 (HER-2) gene copy numbers in breast carcinomas: comparison with HER-2/CEP17 ratio system.
     J Cancer Res Clin Oncol, 133(5): 321-9. [Abstract] [Full-text]
141. Three-dimensional culture models of normal and malignant breast epithelial cells.
     Nat Methods, 4(4): 359-65. [Abstract] [Full-text]
142. Effects of a step-by-step inpatient rehabilitation programme on quality of life in breast cancer patients. A prospective randomised study.
     Onkologie, 30(4): 177-82. [Abstract] [Full-text]
143. Management of the axilla in women with breast cancer.
     Lancet Oncol, 8(4): 331-48. [Abstract] [Full-text]
144. Radial scars/complex sclerosing lesions and malignancy in a screening programme: incidence and histological features revisited.
     Histopathology, 50(5): 607-14. [Abstract] [Full-text]
145. Factors associated with an individual's decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: implications for counseling.
     Genet Test, 11(1): 45-54. [Abstract] [Full-text]
146. Is mastectomy superior to breast-conserving treatment for young women?
     Int J Radiat Oncol Biol Phys, 67(5): 1282-90. [Abstract] [Full-text]
147. Variability among breast radiation oncologists in delineation of the postsurgical lumpectomy cavity.
     Int J Radiat Oncol Biol Phys, 67(5): 1299-308. [Abstract] [Full-text]
148. Prospective trial of accelerated partial breast intensity-modulated radiotherapy.
     Int J Radiat Oncol Biol Phys, 67(5): 1291-8. [Abstract] [Full-text]
149. Shape analysis of microcalcifications using Radon transform.
     Med Eng Phys, 29(6): 691-8. [Abstract] [Full-text]
150. The mannose-binding lectin (MBL2) haplotype and breast cancer: an association study in African-American and Caucasian women.
     Carcinogenesis, 28(4): 828-36. [Abstract] [Full-text]
151. Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells.
     Carcinogenesis, 28(4): 809-15. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.